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ABSTRACT 
Due to continuously high production rates of rhodopsin (RHO) and high metabolic 
activity, photoreceptor neurons are especially vulnerable to defects in proteostasis. A 
proline to histidine substitution at position 23 (P23H) leads to production of structurally 
misfolded RHO, causing the most common form of autosomal dominant Retinitis 
Pigmentosa (adRP) in North America. The AAA-ATPase valosin-containing protein 
(VCP) extracts misfolded proteins from the ER membrane for cytosolic degradation. 
Here, we provide the first evidence that inhibition of VCP activity rescues degenerating 
P23H rod cells and improves their functional properties in P23H transgenic rat and 
P23H knock-in mouse retinae, both in vitro and in vivo. This improvement correlates 
with the restoration of the physiological RHO localization to rod outer segments (OS) 
and properly-assembled OS disks. As a single intravitreal injection suffices to deliver 
a long-lasting benefit in vivo, we suggest VCP inhibition as a potential therapeutic 
strategy for adRP patients carrying mutations in the RHO gene. 
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INTRODUCTION 
Retinitis pigmentosa (RP) is a group of inherited vision disorders causing progressive 
and irreversible degeneration of retinal photoreceptor cells. More than 3,000 mutations 
in over 70 different genes are known to cause non-syndromic RP, and the autosomal 
dominant form (adRP) accounts for approximately 15–25% of cases (1). In turn, over 
150 different mutations in the rhodopsin (RHO) gene have been identified, and 
collectively, they are the most common cause of adRP (2, 3). This gene encodes for 
rhodopsin (RHO) that is expressed by rod photoreceptors and makes up > 80 % of all 
proteins in the disk membranes of the rod photoreceptor outer segments (OS) (4-6). 
The variant RHOP23H is the most common cause of adRP in the United States and is 
the most extensively studied RHO mutation leading to misfolding (7). Structurally 
misfolded RHOP23H is retained within the ER of the inner segment (IS) of rod 
photoreceptor cells, where RHO is synthesized and degraded by ER-associated 
degradation (ERAD) (8).  
ERAD removes misfolded proteins that fail to achieve their native state (9) and thereby 
contributes to proteostasis. In the retina, balanced proteostasis is critical for cell 
survival, and its imbalances for prolonged periods can result in cell death (2). The 
RHOP23H mutation can lead to an accumulation of misfolded mutant protein in the ER 
of photoreceptors and to activation of the unfolded protein response (10), potentially 
with insufficient or imbalanced unfolded protein response output (11). In the long run, 
the presence of RHOP23H results in a metabolic imbalance, mitochondrial failure, and 
ultimately selective photoreceptor cell degeneration (12).  
Transgenic, knock-out, and knock-in (KI) animal models allow scientific investigation 
of retinal degeneration in RP. P23H transgenic rats carry multiple copies of the variant 
RHOP23H allele and are widely used as an animal model for adRP (13). The P23H KI 
mouse model closely reflects the genetic load found in adRP patients. In both animal 
models, the retinae display progressive rod photoreceptor degeneration followed by 
secondary cone degeneration, a phenotype consistent with the clinical findings in 
patients carrying the RHOP23H mutation (14-17).  
The ATPase valosin-containing protein (VCP) is one of the most abundant cytosolic 
proteins. It is mainly localized in the cytosol, with a significant fraction associated with 
organelle membranes, such as the ER and the Golgi (18). In photoreceptors, VCP, 
also known as p97, specifically acts as a quality control checkpoint for membrane 
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proteins (12). VCP is an AAA+ATPase with two ATPase domains (D1 and D2) and is 
equipped with an N-terminal domain that recruits cofactor/substrate specificity factors. 
VCP forms a functional hexamer that acts as an ATP-dependent molecular machine 
(19, 20). It extracts proteins from macromolecular complexes or membranes resulting 
in downstream activity, unfolds ubiquitylated proteins for proteasomal degradation, and 
also functions as an interaction hub, with more than 30 cofactors able to modulate 
VCP-mediated processes (21-24). The ATP hydrolyzing activity of VCP is 
indispensable for its function, and ATP consumption is required to extract incorrectly 
folded proteins from the membranes of the ER or mitochondria (25). 
VCP mutations have been associated with several diseases. Point mutations have 
been linked to multisystem proteinopathy (MSP), also known as IBMPFD (Inclusion 
Body Myopathy associated with Paget's disease of the bone and Frontotemporal 
Dementia) and amyotrophic lateral sclerosis (ALS) (21, 26-30). In these conditions, the 
dysfunction of VCP is considered to result in the deregulation of the proteostasis 
network (26, 31). Conversely, excessive ATPase activity of VCP is also pathogenic 
(32), resulting in mitochondrial fragmentation, cell death in neurons (33), and 
photoreceptor cell degeneration (34).  
In an earlier study, we showed that VCP binds to both normal RHO as well as RHOP23H 
before its release from the ER when expressed in HEK-293 cells (35). Moreover, 
genetic inactivation of VCP in Drosophila carrying the mutant RHOP37H allele (Rh1P37H) 
suppressed retinal pathology (36). Here, we examined whether modulation of the ER-
associated degradation machinery by VCP inhibition could have a therapeutic impact 
on mammalian photoreceptors expressing RHOP23H in two rodent models for adRP.  
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RESULTS 
VCP unfolds and extracts misfolded proteins from the ER membrane in an ATP-
dependent manner. To investigate the effect of inhibition of this highly energy-
consuming step in mammalian photoreceptors, we treated retinae from P23H 
transgenic rats and P23H KI mice with VCP inhibitors. We selected three chemically 
unrelated small-molecule VCP inhibitors, ML240, Eeyarestatin I (EerI), and NMS-873. 
ML240 acts as a selective and reversible ATP-competitive inhibitor of VCP, targeting 
its D2-domain (20, 37, 38). EerI acts as an irreversible inhibitor binding the D1 domain 
of VCP. EerI influences deubiquitinating processes mediated by VCP-associated 
enzymes, but does not inhibit the ATPase activity of purified VCP (38-40). NMS-873 is 
an allosteric ATP- non-competitive VCP inhibitor that binds at the D1–D2 interdomain 
linker and stabilizes the D2-ADP-bound form, highly potent and with high selectivity. 
(19, 31). 
VCP inhibition rescues rod photoreceptors in P23H transgenic rat explanted 
retinae 
We first tested two VCP inhibitors (ML240 and EerI) in a serum-free organotypic culture 
system that preserves the retinal pigment epithelium (RPE) attached to the distal part 
of the OS (41). Organotypic retinal cultures allowed us to test both VCP inhibitors at 
different doses in vitro under standardized conditions. In previous studies, we have 
shown that photoreceptor degeneration in P23H-1 rats starts around postnatal day 
(PN) 9 and peaks at PN15 (14, 42), see Fig. S1. Accordingly, P23H retinae were 
isolated from PN9 and cultivated for six days (Fig. S1). Within this time, photoreceptor 
cell death and regression of the outer nuclear layer (ONL) resembled the process of 
retinal degeneration in vivo. Organotypic cultures were treated every second day with 
ML240 or EerI at different doses in order to select the most effective concentration, 
based on cell survival in the ONL (data not shown). Since both compounds (ML240 
and EerI) require DMSO as vehicle, we selected the lowest amount of DMSO that 
allowed complete solubilization of each compound; thus, corresponding vehicle-control 
groups were treated with 1 % or 0.5 % DMSO, respectively. 
To identify photoreceptors undergoing cell death, we used the TUNEL assay (Fig. 1A), 
which allowed us to determine the percentage of TUNEL-positive dying cells compared 
to the total number of ONL cell nuclei. Both ML240 and EerI significantly reduced the 
percentage of photoreceptor cell death in P23H cultured retinae compared to the 
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respective controls (Vehicle: 6.27 % ± 1.91; ML240: 2.23 % ± 0.36 p<0.0001; Vehicle: 
5.08 % ± 0.41; EerI: 1.70 % ± 0.39 p=0.0004 (Fig. 1B)). This reduction in cell death 
was reflected in an increased number of remaining cell rows in the ONL. Thus, we 
found that the ONL of ML240 and EerI treated P23H retinae contained significantly 
more rows of nuclei compared to the respective controls (Vehicle: 7.75 rows ± 0.76; 
ML240: 9.49 rows ± 0.93 p=0.0026; Vehicle: 8.08 rows ± 0.54; EerI: 9.48 rows ± 0.21 
p=0.0344 (Fig. 1C)). 
Single intravitreal injection of VCP inhibitors to P23H transgenic rats protects 
degenerating rod photoreceptors in vivo 
Next, we evaluated the effect of VCP inhibition in P23H transgenic rats in vivo. To 
avoid potential unwanted systemic effects of VCP inhibition and to be as close as 
possible to clinically approved drug delivery procedures into the eye, we administered 
both compounds (ML240 and EerI) by intravitreal injection. We selected PN10 as the 
injection day and PN15 as our first evaluation time-point, where the peak of 
degeneration in P23H transgenic rats has been observed (Fig. S1). This group was 
designated the short-term (ST) group. Similar to our observations in vitro, five days 
after the injection of VCP inhibitors in the ST group, the TUNEL assay indicated a 
significant decrease in the percentage of dying photoreceptor cells with either ML240 
or EerI (Vehicle: 2.76 % ± 1.30; ML240: 1.20 % ± 0.66 p=0.001; Vehicle: 2.68 % ± 
0.64; EerI: 0.47 % ± 0.27 p<0.0001 (Fig. 2A and B)). Concomitantly, we observed a 
statistically significant increase in the number of remaining cell rows in the ONL in the 
EerI treated retinae during this short period (Vehicle: 9.56 rows ± 0.59; ML240: 9.75 
rows ± 0.54 p>0.99; Vehicle: 10.28 rows ± 0.51; EerI: 11.57 rows ± 0.72 p=0.0003 (Fig. 
2C).  
To estimate the duration of the protective effect, we examined a long-term (LT) group 
that was injected at PN10 and euthanized at PN30 (Fig. S1). We selected this age 
because rat retinae and their photoreceptors reach a mature development level around 
the first postnatal month. We evaluated the number of remaining photoreceptor cell 
rows in the ONL at six locations across both the retina's inferior and superior 
hemispheres. This is because the P23H transgenic rat retinae at P30 show a higher 
degree of photoreceptor degeneration in the superior hemisphere than in the inferior 
hemisphere (15) (Fig. 2D-F). Even 20 days after a single injection, we could detect a 
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significant neuroprotective effect of both ML240 and EerI (Fig. 2E and F, and Table 
S1). This sustained effect was stronger and more pronounced in the superior retina.  
To estimate the intravitreal clearance (CLivt) of the two VCP inhibitors, we performed 
model calculations based on the Quantitative Structure-Property Relationships 
(QSPR) model, that uses comprehensive rabbit data from intravitreal pharmacokinetic 
experiments (43). Assuming similar permeabilities in rat and rabbit RPE, the CLivt (CL 
= P x S, where P is the permeability and S is the RPE's surface area) in the rat would 
be 0.04 ml/h. By using the equation: t1/2 = ln2 Vd/CLivt (t1/2  is the half-life, Vd: is the 
volume of distribution estimated to be similar to the anatomical volume of the vitreous 
(44), of young rats, 25 µl (45)), we calculated the expected half-life in the vitreous to 
be approximately 25 minutes for both compounds. The simulated concentration 
profiles of the in vivo treatment with ML240 and EerI in the rat vitreous are presented 
in Fig. 3, showing more than 98 % of the dose is expected to be eliminated within the 
first 3 hours post-injection. Nevertheless, both VCP inhibitors were still protective at 
PN30, 20 days after injection. This sustained protective effect suggests that the 
mechanisms promoting photoreceptor cell survival started by VCP inhibition remain 
active even after most, if not all, of the VCP inhibitor, has already been eliminated from 
the vitreous. 
VCP inhibition restores RHO localization and increases the OS length in P23H 
transgenic rat retinae in vitro and in vivo 
Some of the features of P23H photoreceptor degeneration are an increase in RHO 
staining in the ONL and IS and the perturbation of the OS structure (17, 46, 47). 
Therefore, we analyzed the effect of VCP inhibition on RHO expression and 
localization by immunofluorescence staining assessing three different parameters: (1) 
distribution of RHO immunostaining in the retina, (2) mean peak of fluorescence 
intensity in the somata (ONL), and (3) length of the OS.  
We used WT rat retinae at PN15 and PN30 as controls. Here, and as previously 
described (48), RHO immunostaining localizes mainly at the OS (Fig. 4A and C, PN15, 
and P30, respectively). In contrast, RHO was abnormally distributed in P23H rod 
photoreceptor cells, similar to observations made in other animal models for RP (49-
51). Here, RHO accumulated in both the ONL and IS of the photoreceptor cells with a 
reduced distribution to the OS (Fig. 4A and C, PN15, and PN30, respectively).  
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To test whether VCP inhibition can correct the decrease of RHO in OS, we evaluated 
RHO immunostaining of P23H retinae treated with either ML240 or EerI in retinal organ 
cultures (in vitro) or the intact eye after intravitreal injections (in vivo). In both sets of 
experiments (in vitro and in vivo), the RHO staining in vehicle-control P23H retinae was 
mislocalized, similar to the untreated retinae (Fig. 4B and C).  
In contrast, VCP inhibition in P23H retinae (in vitro or in vivo) almost completely 
restored RHO's distribution to that of the normal WT phenotype, with staining 
predominantly in the OS. (Fig. 4B, and C). This WT-like distribution suggests that either 
RHO was successfully trafficked from the ER to OS disks or there was enhanced 
removal of the mutant protein and reduction in any dominant-negative effects, unlike 
in the untreated P23H retinae. To measure RHO distribution, we quantified the mean 
peak of fluorescence intensity in the ONL (Fig. 4D). To do so, we selected the ONL 
area in images taken under identical conditions and calculated the fluorescence 
intensity and standard deviation (SD). The observed significant decrease of the mean 
peak of RHO fluorescence intensity in the treated retinae for both in vitro (Vehicle: 
386.70 ± 74.65; ML240: 163.60 ± 56.18 p=0.0048; Vehicle: 405.9 ± 142.4; EerI: 121.10 
± 53.86; p=0.0005; Fig. 4D) and in vivo (Vehicle: 359.80 ± 72.09; ML240: 144.50 ± 
21.68; p=0.0064; Vehicle: 336.50 ± 19.31; EerI: 150.70 ± 27.60; p=0.0191 (Fig. 4D)), 
confirmed the reduced retention of RHO in the ER. Also, measurements of OS length 
supported the hypothesis that there was improved traffic to the OS (Fig. 4E). OS of 
retinae treated with ML240 or EerI were significantly longer, both in vitro (Vehicle: 7.45 
µm ± 0.95; ML240: 15.42 µm ± 0.11; p=0.0007; Vehicle: 7.85 µm ± 0.06; EerI: 14.10 
µm ± 1.59; p=0.0063; Fig. 4E) and in vivo (Vehicle: 14.38 µm ± 0.65; ML240: 33.56 ± 
4.47; p<0.0001; Vehicle: 14.31 µm ± 0.96; EerI: 33.64 µm ± 2.79; p<0.0001; Fig. 4E). 
As RHO composes the vast majority of the total OS integral membrane protein (6), the 
reduction of RHO staining in the ONL accompanied by an increase of the OS length 
strongly suggest that RHO is no longer retained in the IS once VCP is inactivated, 
allowing proper membrane localization and translocation to the OS. 
At this point, we found similar protective characteristics between ML240 and EerI. To 
more efficiently use laboratory animals and following the 3Rs - reducing, refining, and 
replacing animal use (52), we decided to select only one of the compounds for further 
experiments. Inhibition with EerI is irreversible and unspecific (inhibition of other 
cellular components, including ataxin 3 and Sec61), and it has been suggested that 
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EerI needs to be metabolized into an active compound to exert its inhibitory effect (31, 
39, 53). In contrast, VCP inhibition by ML240 works by a defined mechanism of action, 
is reversible, and ML240 has low off-target activity compared to EerI. Within the context 
of the Ubiquitin/Proteasome System, ML240 is specific for VCP, is far-better 
characterized in terms of VCP-dependent processes, and selectively inhibits the D2 
ATPase domain of VCP (19, 20, 38). For these reasons, we focused on VCP inhibition 
by ML240 for the ultrastructure analysis and the retinal function evaluation in the P23H 
rat model of RP. 
VCP inhibition corrects P23H destabilization in rod disk membranes in P23H rats 
We used electron microscopy (EM) to analyze how the improvement in the RHO 
localization and cell survival due to VCP inhibition affected OS's ultrastructural 
properties, especially concerning OS disk structure and organization. Again, we 
included both in vitro and in vivo paradigms. For in vitro assessment, P23H retinae 
were explanted at PN20 and treated with ML240 for two days to evaluate the acute 
effect of VCP inhibition. For in vivo assessment, we intravitreally injected ML240 at 
PN10 and analyzed the eyes at PN21 (Fig. S1). We selected this time-point as the 
photoreceptor structure has fully matured after PN20 (54). Reynold's lead citrate-
stained semi-thin sections of the treated explants showed longer and morphologically 
more homogeneously structured OS than vehicle controls (Fig. 5A and B).  
EM examination in WT rat retinae displayed OS discs consisting of a double lamellar 
membrane connected by a rim region (5) (Fig. 5C and E). In vitro or in vivo control 
P23H retinae (untreated or treated with vehicle) revealed abnormal OS disk 
membranes displaying multiple vesicotubular structures similar to those described in 
rhoP23H-EGFP transgenic Xenopus and RhoP23H transgenic mice (55), accompanied by 
broken disk bilayers (Fig. 5C – F). Retinae treated with ML240 showed strongly 
reduced vesiculation and less ruptured discs in organotypic culture as well as in 
intravitreally treated eyes (Fig. 5C and F). We calculated the percentage of OS 
displaying a correct-structured lamellation in ML240 treated retinae compared to 
vehicle-treated controls. We observed an almost 3-fold increase in vitro (Vehicle: 21.88 
% ± 1.78; ML240: 59.44 % ± 7.92; p=0.0010) and a significant increase also in vivo 
(Vehicle: 52.42 % ± 11.68; ML240: 84.66 % ± 7.91; p=0.0025; Fig. 6) after treatment. 
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ML240 treatment results in an improvement of retinal function in P23H rats 
To investigate whether the observed preservation of photoreceptor cell viability and 
structure and improved RHO distribution in P23H retinae after VCP inhibition resulted 
in improved retinal function, we assessed the retina's light responsiveness in vitro and 
in vivo. 
Using a Multi-electrode array (MEA) system, we evaluated the response to light 
stimulation of PN20 retinae explanted and kept in vitro for two days. These organotypic 
cultures were treated with ML240 and compared to vehicle-treated controls. We 
positioned the explants on the MEA, excited them using blue light flashes, and 
recorded the resulting retinal activity (Fig. 7A). Light responsiveness of ML240 treated 
retinae was significantly increased when compared to vehicle-treated controls. In 
ML240 treated explants, the percentage of electrodes detecting light-induced activity 
was approximately six times higher for the ganglion cell activity (Spikes: Vehicle: 9.69 
± 5.33; ML240: 59.75 ± 22.33; p<0.001 (Fig. 7B)) with an activated ganglion cell type 
distribution of 51.48 % ON, 11.33 % OFF and 37.20 % ON-OFF (Fig. 7C). Along with 
this, the micro electroretinogram (mERG) indicated a response of more than 80 % of 
the electrodes in treated retinae and an almost absent response in the control group 
(mERG: Vehicle: 0.97 ± 1.65; ML240: 84.02 ± 11.32; p<0.0001; Fig. 7B). We also 
evaluated the retinal explants' light responsiveness to 20 repetitive light flashes and 
found that treated explants showed a more than three-fold increased average light 
response per recording electrode (Vehicle: 2.51 ± 1.96; ML240: 9.28 ± 5.65; p<0.0001; 
Fig. 7D). 
To assess the effect of VCP inhibition on retinal function in vivo, P23H rats received a 
single intravitreal injection of ML240 at PN10, and retinal function was assessed by 
full-field scotopic electroretinogram (ERG) in dark-adapted rats between PN19 and 
PN21. Light exposure correlates with an increased a-wave corresponding to 
photoreceptor hyperpolarization, followed by a b-wave response to light corresponding 
to depolarization of retinal cells post-synaptic to the photoreceptors. In ML240 treated 
retinae, we observed an increased response to light, as evidenced by higher ERG 
responses. Both scotopic a-wave and b-wave amplitudes were increased compared to 
those of vehicle-treated eyes (e.g., 0 log 10 cd s−1 m−2, a-wave: Vehicle: 46.41 ± 4.63 
V; ML240: 63.11 ± 6.72 V; p= 0.0102. b-wave: Vehicle: 221.50 ± 20.15 V ; ML240: 
281.10 ± 29.40 V; p= 0.0412 (Fig. 8A)). Putting these data together, the overall effect 
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of ML240 on visual function, determined by scotopic ERGs, indicates an increased 
light response compared to the vehicle-treated retinae (a-wave: F=10.83, p=0.0013; b-
wave: F=7.96; p= 0.0055 (Fig. 8B and C, and Table S2)). 
In conclusion, VCP inhibition by ML240 resulted in improved retinal function correlating 
with increased cell survival, preserved photoreceptor morphology, and RHO's 
corrected distribution. 
The allosteric VCP inhibitor NMS-873 improves the photoreceptor survival and 
the retinal function in the P23H KI mouse model 
Besides competitive VCP inhibitors like ML240, other VCP inhibitors act in an allosteric 
manner. One of them is the NMS-873, one of the most potent and specific VCP 
inhibitors described to date, which shows high stability, specificity, and potency (31, 
56-59). NMS-873 inhibits both ATPase domains of VCP, whereas ML240 is specific 
for D2 (19). In order to double-check if the obtained effects are due to VCP inhibition, 
and following the same experimental rationale, we tested the NMS-873 in a serum-free 
organotypic culture system, and then we performed in vivo intravitreal injections in the 
heterozygous P23H KI mouse model. P23H KI retinae were isolated from PN14 and 
cultivated for six days (Fig. 9). Tissues were treated every second day with 5 µM NMS-
873, and the vehicle-controls were treated with DMSO.  
The percentage of TUNEL-positive cells compared to the total number of ONL cell 
nuclei was significantly reduced by NMS-873 treatment (Vehicle: 4.53 % ± 1.94; NMS-
873: 2.06 % ± 0.94 p=0.04 (Fig. 9B)). Thus, the increased survival was reflected in the 
increased number of remaining cell rows in the ONL (Vehicle: 6.04 rows ± 2.06; NMS-
873: 8.63 rows ± 1.12 p=0.026 (Fig. 9C)). 
Next, we evaluated the effect of VCP inhibition by NMS-873 in P23H KI mice in vivo 
by intravitreal injection. We selected PN11 as the injection day and PN21 as our 
evaluation time-point. Similar to our observations in vitro and in vivo the previous 
results with ML240 and EerI, we found a significant decrease in the percentage of 
TUNEL-positive photoreceptor cells after VCP inhibition (Vehicle: 1.47 % ± 0.46; NMS-
873: 0.51 % ± 0.12 where p=0.043 (Fig. 9E)), as well as a statistically significant 
increase in the number of remaining cell rows in the ONL (Fig. 9 F, and Table S3). As 
seen in ML240 and EerI in the P23H rats, NMS-873 also restored RHO distribution in 
P23H KI mice in vitro and in vivo.  
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Photoreceptor function was assessed by full-field scotopic ERG in dark-adapted P23H 
KI mice at PN21. Both scotopic a-wave and b-wave amplitudes were increased 
compared to those of vehicle-treated eyes (a-wave: F=4.22, p=0.0447; b-wave: 
F=8.69; p= 0.0047 (Fig. 9G and H, respectively, and Table S4).  
These results confirm the protective effect of VCP inhibition by three different types of 
inhibitors and even in two different RP animal models, P23H transgenic rats and P23H 
KI mice. 
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DISCUSSION 
VCP has been considered an anti-cancer target, with a VCP inhibitor CB-5083 
evaluated in phase 1 clinical trials, NCT02223598 and NCT02243917 (60). Therefore, 
the pro-survival and neuroprotective effect observed after inhibition of VCP appears 
counterintuitive at first glance. We report here that VCP inhibition attenuates adRP 
disease progression in the P23H mediated animal model of RP. In contrast to the effect 
on cancer cells (i.e., induction of apoptosis), in photoreceptors expressing mutant 
RHOP23H, VCP inhibition significantly increases survival and functionality. VCP 
inhibition also corrects RHO's aberrant distribution and restores physiological 
localization similar to that of the WT phenotype.  
Previous studies have revealed that misfolded RHOP23H is retained in the ER and is 
removed by ERAD (61). VCP interacts with misfolded RHOP23H, promoting its retro-
translocation and proteasomal clearance (35). In the transgenic Drosophila Rh1P37H 
(the equivalent of mammalian RHOP23H), inhibition of VCP leads to structural and 
functional improvements of the insect eye (36). In agreement with these observations, 
ultrastructural analysis by EM confirmed the improvement of morphology within the OS 
of treated P23H rats. The typical mislocalization of RHO immunostaining observed in 
the P23H retinae was almost completely corrected to its physiological localization 
within OS. However, at this point, it remains unclear whether RHOP23H, RHOWT, or both 
are trafficked from the IS to the OS. In Drosophila, RHO mutants can recruit WT RHO 
into intracellular aggregates (62-64). In contrast to that, recent studies suggest that in 
mammalian cells, misfolded RHOP23H does not aggregate with properly folded RHOWT 
(65, 66), although other evidence does suggest there is a dominant-negative effect of 
RHOP23H on the WT protein (2, 67).  
We found elongated OS in all groups treated with VCP inhibitors. Since RHO is the 
most abundant integral membrane protein of OS, representing >90 % of all protein 
localized in this compartment (5, 6), the observed elongation is likely resulting from 
enhanced membrane traffic of RHO to the OS and its reduced retention in the ER. VCP 
inhibition might lead to recovered RHO distribution by several potential mechanisms: 
either a redistribution of RHOP23H, improvement RHOP23H folding or a decrease of 
RHOWT degradation. Since the two major intracellular protein degradation systems are 
proteasomal degradation and autophagy, another option is increased degradation of 
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RHOP23H via upregulated autophagy as compensation for the attenuated proteasomal 
degradation (68, 69). However, further studies are necessary to clarify this. 
Previous reports have established a destabilizing effect of misfolded RHO on the disk 
membranes of OS, potentially mediated by aggregation of the mutated unstable 
RHOP23H. Aggregates formed by RHOP23H could disrupt the correct membrane 
structure, resulting in vesiculotubular structures and disk breakdown (55, 70). With 
ML240 treatment, we observed a marked reduction of the vesiculotubular structures in 
the OS of the P23H rat model retinae. Following Haeri and Knox's hypothesis, this may 
result from a change in the RHOP23H/RHOWT ratio in the disk membrane. Thus, less 
RHOP23H and/or increased RHOWT would lead to fewer protein aggregates in the OS 
and a reduced formation of vesiculotubular structures. Two mechanisms could be 
involved in altering the balance between mutant and WT protein. As excessive protein 
retrotranslocation has been described in the Rh1P37H insect model (36, 68), VCP 
inhibition may impair this retrotranslocation and consequently increase the amount of 
RHOWT as well as Rh1P37H that reaches the OS disk membrane. Alternatively, as VCP 
is related to selective autophagy modulation (71, 72), rebalancing the autophagic 
pathway may reduce retinal degeneration caused by protein misfolding (73). In fact, it 
has been suggested that in the retina of P23H mice, normalization of the autophagic 
flux relative to proteasome activity may support photoreceptor cell homeostasis, 
resulting in increased photoreceptor cell survival (74). 
The improvements in RHO localization and OS structure mediated by VCP inhibition 
were accompanied by significant photoreceptor function improvements, as determined 
by light responsiveness in the retinal explants and ERG responses in vivo. The 
improved photoreceptor function is likely to reflect a combination of enhanced 
photoreceptor survival and improved photoreceptor homeostasis. At the time points 
studied, short and medium-term in explants and in vivo, the functional improvements 
observed were greater than the effects on survival, suggesting that photoreceptor 
homeostasis restoration could be a significant factor contributing to the enhanced light 
responses. This effect could occur due to a combination of a reduction in an inhibitory 
effect of misfolded RHOP23H on RHO activation or regeneration and restoration of the 
OS structure, enabling improved phototransduction. The enhanced photoresponses 
further illustrate the potential benefit of VCP inhibition as a potential therapy.  
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Our previous work revealed altered energetic patterns and metabolic failure prior to 
retinal degeneration in the Drosophila Rh1P37H model (12). When analyzing the 
proteome of young Rh1P37H retinas, we observed a coordinated upregulation of energy-
producing pathways and an attenuation of energy-consuming pathways involving the 
target of rapamycin (TOR) signaling, which was reversed in older retinas at the onset 
of photoreceptor degeneration. With a combination of pharmacological and genetic 
approaches, we demonstrated that chronic suppression of TOR signaling (using the 
inhibitor rapamycin) strongly mitigated photoreceptor degeneration, indicating TOR 
signaling activation by chronic Rh1P37H proteotoxic stress is detrimental for 
photoreceptors. Genetic inactivation of the ER stress-induced JNK/TRAF1 axis and 
the APAF-1/caspase-9 axis, activated by damaged mitochondria, dramatically 
suppressed Rh1P37H-induced photoreceptor degeneration, identifying the mitochondria 
as mediators of Rh1P37H toxicity. Thus, the distortion of photoreceptors' energetic 
profile leading to a prolonged metabolic imbalance accompanied by the mitochondrial 
failure may be a driving force for photoreceptor degeneration associated with a 
RHOP23H mutation. Therapies normalizing metabolic function could be used to alleviate 
the imbalance associated with excessive energy wasting in photoreceptor cells. In line 
with this consideration, it has been shown that inhibition of the ATPase activity of VCP 
can exert neuroprotection of photoreceptors in an animal model of recessive RP (75, 
76), ganglion cell death in a glaucoma model (77), as well as ameliorate retinal 
ischemia (78). Thus, we hypothesize that the high energy cost necessary for removing 
misfolded RHOP23H (79) is mitigated by targeting VCP ATPase domains, resulting in 
stemmed loss of photoreceptors and better retinal functionality.  
It is worth noting the sustained protective effect after a single injection of both VCP 
inhibitors. The usual half-life range for small molecules is between 1–10 hours since 
small lipophilic compounds are cleared rapidly across the blood-ocular barriers to the 
systemic bloodstream (80-82). We calculated the expected vitreal half-life for both 
ML240 and EerI to be approximately 25 minutes, with 98 % being eliminated within 3 
hours. Despite this estimated short half-life, both VCP inhibitors remain protective until 
PN30, 20 days after the single injection. The sustained effect suggests a prolonged 
mode of action pertaining to photoreceptor cell survival or a mechanism of selective 
drug retention. In fact, the vitreous and iris can serve as a reservoir for drugs and as a 
temporary storage depot for metabolites (83, 84). Drug protein binding likely increases 
retention, given that proteins have a much higher half-life in the vitreous than small 
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molecules (82). EerI acts as an irreversible inhibitor of VCP (38, 85), a fact that could, 
at least partially, explain a long-lasting effect. However, NMS-873 and ML240 are 
reversible VCP inhibitors (19, 38), and their sustained protective effect is evident. Thus, 
it remains unexplained how exactly the drug to target binding or an off-target binding 
of these compounds contributes to the observed prolonged effect.  
We were able to reproduce the neuroprotective achievements using a different kind of 
inhibitor, NMS-873, and in a second animal model, the P23H KI mice, which more 
accurately models the human genotypic and phenotypic RHOP23H. 
Taken together, this study demonstrates a pre-clinical proof of concept that VCP 
inhibition can effectively attenuate retinal degeneration caused by protein misfolding in 
mammalian photoreceptors. In humans, retinal degeneration, due to a RHOP23H 
mutation, takes on average three decades before legal blindness is reached. This 
finding opens a decent therapeutic window for a potential clinical application of VCP 
inhibition, far longer than in the rodent model. Future studies, however, are necessary 
to assess drug administration's safety as a primary endpoint, followed by clinical 
studies to improve visual outcome in retinal degeneration caused by the RHOP23H 
mutation in humans. 
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METHODS  
Animals 
Homozygous P23H transgenic rats (produced by Chrysalis DNX Transgenic Sciences, 
Princeton, NJ) of the line SD-Tg(P23H)1Lav (P23H-1) were kindly provided by Dr. M. 
M. LaVail (University of California, San Francisco, CA) or by the Rat Resource and 
Research Center (RRRC) at the University of Missouri. Animals were housed in the 
animal facilities of both the Institute for Ophthalmic Research and the University 
College London, under standard white cyclic lighting, with access to food and water ad 
libitum. To reflect the genetic background of adRP, we employed heterozygous P23H 
rats obtained by crossing with WT rats (CDH IGS Rat; Charles River, Germany). 
RhoP23H/P23H (P23H KI) mice were kindly provided by Dr. K. Palczewski (University of 
California, Irvine, CA) or purchased from Jackson Laboratory (B6.129S6(Cg)-
Rhotm1.1Kpal/J, Stock No 017628). The RhoP23H/P23H mice were crossed with WT 
C57BL/6J mice to produce P23H heterozygous mice to reflect the genetic background 
of adRP. 
Organotypic Retinal Explant Cultures of P23H transgenic rats and P23H KI mice 
Retinae were isolated with the RPE attached as described previously (41, 86). Briefly, 
PN9 and PN20 P23H transgenic rats were sacrificed; the eyes were enucleated in an 
aseptic environment and pretreated with 12 % proteinase K (MP Biomedicals, 
0219350490) for 15 minutes at 37 °C in R16 serum-free culture medium (Invitrogen 
Life Technologies, 07490743A). The enzymatic digestion was stopped by the addition 
of 20 % FBS (Sigma-Aldrich, F7524). Retina and RPE were dissected, and four radial 
cuts were made to flatten it. Tissue was transferred to a 0.4 µm polycarbonate 
membrane (Corning Life Sciences, CLS3412), having the RPE side touching the 
membrane. The inserts were placed into six-well culture plates and incubated in 
supplemented R16 nutrient medium at 36.5 °C. The eyes were then randomly assigned 
to either untreated, vehicle, or VCP inhibitor groups. The VCP inhibitor cultures were 
treated with either ML240 (20 µM, TOCRIS, Bio-Techne GmbH, 5153) or Eeyarestatin 
I (10 µM, TOCRIS, Bio-Techne GmbH, 3922). Both compounds were pre-diluted in 
DMSO (Sigma-Aldrich D2650). DMSO (1% and 0.5%, respectively) was diluted in the 
culture medium to generate the corresponding vehicle controls. The medium was 
changed every second day. The PN9 cultures were fixed at DIV6, which correspond to 
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PN15, the peak of degeneration in vivo age-matched mutants. The PN20 cultures were 
fixed at DIV2.  
P23H KI heterozygous mice were sacrificed at PN14, and the eyes were enucleated 
in an aseptic environment. Retinal explants were randomly assigned to either vehicle 
or 5µM NMS-873 (Xcessbio, M60165-b) treatment. The medium was changed every 
second day, and retinae cultures were fixed at DIV6, which correspond to PN20, the 
peak of degeneration in vivo age-matched heterozygous P23H KI mice. 
In vivo treatment 
We divided the transgenic rats into three experimental groups: short-term (ST), retinae 
analyzed at PN15, medium-term (MT), retinae analyzed at PN21, and long-term (LT), 
retinae analyzed at PN30. A single intravitreal injection of ML240 or EerI to all P23H 
rats previously anesthetized (ST and LT: Diethyl ether, Merck Millipore, 100931, or MT: 
intraperitoneal injection of ketamine (30 mg/kg) and medetomidine (5 mg/kg)) took 
place at PN10 at the level of the temporal or nasal peripheral retina. Assuming an 
average rat eye volume of ~25 µl at PN10-30 (45), and an even compound distribution, 
and in order to achieve the same concentration as in the organotypic cultures (20 µM 
of ML240 and 10 µM of EerI), the animals received intravitreally 1 µl of 0.4 mM ML240 
or 0.5 µl of 0.4 mM EerI on the right eye. The left eye was sham injected with the same 
volume of vehicle solution and served as contralateral control.  
A single intravitreal injection of NMS-873 was performed at PN11 in previously 
anesthetized (ketamine/medetomidine at 0.08 ml/10 g administered via an IP injection) 
P23H KI mice in the temporal peripheral retina. Assuming an average mice eye 
volume, at PN11, is ~5µl (87) and in order to achieve the same concentration as in the 
organotypic cultures, 5 µM NMS-873, the animals received intravitreally 0.5 µl of 0.05 
mM NMS-873 on the one eye while another eye was sham injected with the same 
volume of vehicle (DMSO) solution. Animals were monitored daily for any adverse 
effects and for body weight gain. At PN21, mice were subjected to ERG before they 
were humanely killed by cervical dislocation.  
Assessing the intravitreal clearance of ML240 and EerI 
The CLivt of ML240 and EerI were calculated in silico using the QSPR model (43). 
However, one should notice that ML240 and EerI are found to be more lipophilic than 
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted November 19, 2020. ; https://doi.org/10.1101/2020.11.17.384669doi: bioRxiv preprint 
19 
 
the compounds used in building the model, and thus, the model predictions may not 
be accurate, but anyway, give an approximation for vitreal drug elimination. The CLivt 
value of ML240 and EerI was calculated using the QSPR equation: 
LogCLivt = −0.25269–0.53747 (LogHD) + 0.05189 (LogD7.4), where HD is the number 
of hydrogen bond donor atoms and LogD7.4 is the calculated logarithm of the octanol-
water coefficient at pH 7.4 of ML240 and EerI. Since small lipophilic compounds are 
cleared from the vitreous mainly through the RPE (44), the CLivt obtained in rabbit eyes 
was scaled down to rat eyes. Based on the equation CLivt = P × S, (P: drug permeability 
in the RPE, S: surface area of the RPE), the CLivt of small lipophilic compounds in rats 
was expected to be ~13 times smaller than in rabbits. The RPE surface areas in rats 
and rabbits are 39 mm2 (88) and 520 mm2 (89), respectively. Assuming similar 
permeability of rat and rabbit RPE, the CLivt in the rat would be 0.04 ml/h (rabbit value: 
0.58 ml/h for ML240, and 0.55 ml/h for Eerl). The volume of distribution (Vd) after 
intravitreal injection is similar to the anatomical volume of the vitreous (43), so that 25 
µL for the rats used in the current project (PN10-30) (45). The expected half-life in the 
vitreous was calculated using the equation: t1/2 = ln2 Vd/CLivt. 
Histology 
Tissues were immersed in 4 % paraformaldehyde in 0.1 M phosphate buffer (PB; pH 
7.4) for 45 minutes at 4 °C, followed by cryoprotection in graded sucrose solutions (10 
%, 20 %, 30 %) and embedded in cryomatrix (Tissue-Tek® O.C.T. Compound, 
Sakura® Finetek, VWR, 4583). Radial sections (14 µm thick) were collected, air-dried, 
and stored at -20 °C. 
TUNEL assay: TUNEL assay (90) was performed using an in situ cell death detection 
kit conjugated with fluorescein isothiocyanate (Roche, 11684795910). DAPI 
(Vectashield Antifade Mounting Medium with DAPI; Vector Laboratories, H-1200) was 
used as a nuclear counterstain.  
Immunofluorescence staining and image analysis: Sections were incubated overnight 
at 4 °C with RHO mAb (Sigma-Aldrich, MAB5316). Fluorescence 
immunocytochemistry was performed using Alexa Fluor® 568 conjugated secondary 
antibody (Invitrogen, A- 11031). Negative controls were carried out by omitting the 
primary antibody. The RHO staining's immunofluorescence intensity was calculated, 
scoring the mean maximum intensity for a selected central ROI of the ONL of each 
image within 12 images from three animals per treatment using the Zen 2.3 software. 
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The OS mean length was obtained using the Zen 2.3 software for three selected 
positions for each image, measuring the OS's length within 15 (in vitro) or 12 images 
(in vivo) from three animals per treatment.  
Transmission Electron Microscopy 
Retinal samples were fixed in 2.5% glutaraldehyde, 2 % paraformaldehyde, 0.1 M 
sodium cacodylate buffer (pH 7.4, Electron Microscopy Sciences, Germany) overnight 
at 4°C. After rinsing, samples were postfixed in 1 % OsO4 for 1.5 hours at room 
temperature (Electron Microscopy Sciences, Germany), washed in cacodylate buffer, 
and dehydrated with 50 % ethanol. Tissues were counterstained with 6 % uranyl 
acetate dissolved in 70 % ethanol (Serva, Heidelberg, Germany) followed by graded 
ethanol concentrations up to 100 %, followed by Propylenoxide. The dehydrated 
samples were incubated in a 2:1, 1:1, and 1:2 mixture of propylene oxide and Epon 
resin (Serva, Germany) for 1 hour each. Finally, samples were infiltrated with pure 
Epon for 2 hours. Samples were embedded in fresh resin in block molds and cured 3 
days at 60°C. Ultrathin sections (50 nm) were cut on a Reichert Ultracut S (Leica, 
Germany), collected on copper grids, and counterstained with Reynold's lead citrate. 
Sections were analyzed with a Zeiss EM 900 transmission electron microscope (Zeiss, 
Jena, Germany) equipped with a 2k x 2k CCD camera. 
Ex-vivo light stimulation and activity recordings  
P23H rat retinal explants (PN20 DIV2) were taken under dim red light condition (boxed) 
from the incubator, divided into half across the center, and placed immediately on the 
recording electrode field of the recording multi-electrode array (MEA) chamber. The 
recording was performed within the culturing medium, and the recording chamber 
temperature was set to 37 °C.  
Retinal activity recording: The MEA system USB-MEA60-Up-BC-System-E (Multi 
Channel Systems) equipped with HexaMEA 40/10iR-ITO-pr was utilized to record the 
retinal activity based on 59 recording electrodes. The recordings were performed at 
25000 Hz sampling rate collecting unfiltered raw data. The trigger synchronized 
operation of the light stimulation (LEDD1B T-Cube, Thorlabs) and MEA-recording were 
controlled by the recording protocol set within the MCRack software (v 4.6.2, MCS) 
and the digital I/O – box (MCS). 
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Light stimulation: The light stimulation (470 nm LED M470D2, Thorlabs) was applied 
from beneath the transparent glass MEA guided by optic fiber and optics. A 
spectrometer USB4000-UV-VIS-ES (Ocean Optics) was employed to determine the 
intensity of the applied light stimuli (35 cd/m²), pre-recordings. 
Electroretinogram 
PN19-21 P23H rats or PN21 P23H KI mice were kept overnight in a ventilated light-
tight box for dark-adaption. Subsequent procedures were performed under dim red 
light conditions. Animals were anesthetized, and pupils were dilated using 1.0% 
tropicamide (Bausch&Lomb). Scotopic ERG was performed using the Celeris-
Diagnosys system and Espion software (Diagnosys, LLC, MA). Bilateral electrodes 
were positioned on rat's eyes using a liquid gel (Viscotears, Novartis, AG); to produce 
increasing simultaneous flash stimuli and record retinal activity. For the full-field 
scotopic ERG, a 7-step protocol was used with the following intensities: 0.0001 (1.03 
Hz), 0.001 (1.03 Hz), 0.01 (0.5 Hz), 0.1 (0.1 Hz), 1 (0.05 Hz), 10 (0.04 Hz), 30 (0.04 
Hz) cd s−1 m−2; with short dark-adaption pause in between. For each step, 3 to 10 
recordings were displayed and averaged. 
Microscopy and cell counting 
All samples were analyzed using a Zeiss Axio Imager Z1 ApoTome microscope, 
AxioCam MRm camera, and Zeiss Zen 2.3 software in Z-stack at 20x magnification. 
For quantitative analysis, positive cells in the ONL of at least three sections per group 
were manually counted. The percentage of positive cells was calculated, dividing the 
number of positive cells by the total number of ONL cells. Photoreceptor cell rows were 
assessed by counting the individual nuclei rows in one ONL and averaging the counts.  
Graphs were prepared in GraphPad Prism 7.05 for Windows; Adobe Photoshop CS5 
and Corel DRAW X5 were used for image processing. 
Statistics  
All data, unless otherwise indicated, were analyzed and graphed using GraphPad 
Prism 7.05 for Windows. P < 0.05 was considered significant. 
TUNEL counts, photoreceptor row counts, RHO immunofluorescence intensity, and 
OS length: The evaluation was performed using one-way ANOVA testing, followed by 
Bonferroni multiple comparisons test. For multiple comparisons in the inferior and 
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superior retinae in the LT group in vivo, two-way ANOVA testing, followed by 
Bonferroni multiple comparisons test, was conducted. 
MEA-recording: For the electrophysiology data analysis, custom-developed scripts 
(MATLAB, The MathWorks) were used, if not indicated otherwise. MEA-recording files 
were filtered employing the Butterworth 2nd order (MC-Rack, Multi-channel systems) 
to extract the ganglion cell spikes (high pass 200 Hz) and field potentials (bandpass  
2 – 40 Hz). The field potentials recorded by the MEA system corresponds to the human 
ERG as described mERG by (91). The filtered data were converted to *.hdf files by MC 
DataManager (v1.6.1.0) for further data processing in MATLAB (spike detection and 
cell-type determination (ON, OFF, and ON-OFF)) as previously described (92, 93). The 
Man-Whitney-U test was employed to estimate statistical significance. 
ERG data analysis. For one-to-one comparisons (vehicle-treated vs. treated), a paired 
Student's t-test was implemented. For multiple comparisons, two-way ANOVA testing, 
followed by Bonferonni multiple comparisons test, was conducted for a- and b-wave 
ERG amplitudes for all stimulus intensities to compare the effect of ML240 or NMS-
873 on retinal function.  
Study approval 
Procedures were approved by the Tuebingen University committee on animal 
protection (§4 registrations from 24.04.2013 and AK 15/18 M, and animal permit 
AK1/13 for P23H transgenic rats, §4 registrations from 12.08.2019 AK 05/19 M for 
P23H KI mice) and by the UCL Institute of Ophthalmology, London, UK, ethics 
committee according to the Home Office (UK) regulations, under the Animals 
(Scientific Procedures) Act of 1986, and performed in compliance with the Association 
for Research in Vision and Ophthalmology ARVO Statement on animal use in 
ophthalmic and vision research. All efforts were made to minimize the number of 
animals used and their suffering. 
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FIGURES 
 
 
Figure 1. Neuroprotective effect of VCP inhibition in organotypic cultures of P23H 
retinae. Retinae from P23H transgenic rats were explanted at postnatal day 9 (PN9), kept for 
6 days in vitro (DIV6), and treated every second day with either 20 µM ML240 or 10 µM 
Eeyarestatin (VCP inhibitors). ML240 and EerI were dissolved in the smallest practical volume 
of DMSO, and corresponding controls were treated using the same vehicle volume. (A) 
Explants were stained with TUNEL assay to differentiate photoreceptors undergoing cell death 
(green) using nuclei counterstaining with DAPI (blue). (B) Bar chart shows the percentage of 
TUNEL-positive cells in the ONL. A significant decrease in the percentage of dying cells was 
observed after treatment with either ML240 or EerI compared to the respective vehicle controls. 
(C) Comparison of the number of remaining cell rows in the ONL. Retinae treated with VCP 
inhibitors showed significant preservation of the number of photoreceptor cell rows. Values 
were quantified by scoring several images (open circles) from at least four retinae (closed 
circles, n=4) per treatment. Data plotted as mean ± SD. One-way ANOVA with Bonferroni 
multiple comparison test; ***p<0.001; **p<0.01, *p<0.05. RPE: retinal pigment epithelium; 
ONL: outer nuclear layer; INL: inner nuclear layer. Scale bar: 50µm. 
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Figure 2. Single intravitreal injection of VCP inhibitors to P23H transgenic rats protects 
degenerating rod photoreceptors in vivo. Intravitreal injections in P23H rats were performed 
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at postnatal day 10 (PN10). For the analysis, the animals were divided into short-term (retinae 
fixed at PN15, A-C) and long-term (retinae fixed at PN30 D-F). (A) Representative images of 
the stained retinae fixed at PN15 using the TUNEL assay to differentiate photoreceptors 
undergoing cell death (green) and nuclei counterstaining using DAPI (blue). (B) Bar chart 
shows the percentage of TUNEL-positive cells in the PN15 fixed retinae. In the short term 
treated group, both ML240 and EerI significantly reduced the number of dying cells compared 
to the respective vehicle control (contralateral retina) in the P23H mutant. (C) Quantification of 
the ONL cell rows for the PN15 fixed retinae. Only in the EerI treated group a significant 
increase in the number of remaining cell rows in the ONL 5 days after treatment was observed. 
(D) Representative images of the radial parasagittal sections showing inferior (I) and superior 
(S) hemispheres of the retinae stained with DAPI (blue) of vehicle, ML240, and EerI long-term 
treated groups. (E and F) Retinal spidergrams of the inferior and superior hemispheres along 
the vertical meridian revealed that treated retinae (E: ML240 in green, F: EerI in blue) contain 
more nuclei rows in the ONL than the contralateral vehicle-treated retinae. The neuroprotective 
effect is stronger in the superior retina. Values were quantified by scoring several images (open 
circles) from at least four retinae (closed circles, n=4) per treatment. Plotted data as mean ± 
SD. One-way ANOVA with Bonferroni multiple comparison test; (B-C) or Two-way ANOVA with 
Bonferroni multiple comparison test; (E-F). ***p<0.001; **p<0.01; *p<0.05. ONL: outer nuclear 
layer; INL: inner nuclear layer; ONH: optic nerve head. Scale bar: 50µm. 
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Figure 3. Simulated concentration profiles of ML240 and Eerl. After intravitreal injection of 
0.5 nmol and 0.25 nmol dose respectively in the rat vitreous, using the estimated rat 
pharmacokinetic parameters of intravitreal clearance 0.04 ml/h and volume of distribution 25 
µL for both analyzed groups, the expected half-life was calculated to be approximately 25 
minutes; thus, more than 98 % of both drugs is expected to be eliminated in the first 3 hours 
after injection. Since ML240 and EerI were still protective 20 days after the single injection, 
mechanisms promoting photoreceptor cell survival started by VCP inhibition presumably 
remain active even after most of the drug has already been eliminated from the vitreous. 
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Figure 4. VCP inhibition restores RHO localization and increases OS length in P23H 
transgenic retinae in vitro and in vivo. Immunofluorescence labeling in cryosections 
designates the location of RHO (red staining) in (A) Untreated WT and P23H control retinae 
at PN15; (B) organotypic cultures of P23H retinae, explanted at postnatal day 9 and cultivated 
for 6 days (PN9 DIV6), treated with vehicle, ML240, or EerI; and (C) PN30 in vivo retinae from 
untreated WT and P23H and treated P23H rats (after a single injection at PN10 of vehicle, 
ML240, or EerI). Untreated WT retinae at PN15 and PN30 as a point of reference, as staining 
in WT, was exclusively observed in the OS. In contrast, in P23H untreated retinae, RHO 
staining was observed in both the ONL and the OS, indicating an accumulation in the mutants' 
cell somata. In the vehicle control groups, in vitro, as well as in vivo, an abnormal RHO 
distribution was observed, with strong fluorescence staining in the ONL and very short rod OS. 
In retinae treated with VCP inhibitors - in vitro and in vivo - we found a reduction of the 
fluorescence in the ONL and better preserved and longer OS. VCP inhibitors were able to 
restore the distribution of RHO predominantly to the OS and increased OS length. (D) 
Quantification of RHO immunofluorescence intensity in the ONL in vitro and in vivo. A central 
region of each image was selected, and the mean maximum intensity was assessed using the 
Zen 2.3 software. In vitro, as well as in vivo, VCP inhibition reduced the FL intensity in the 
ONL. (E) The mean length of the OS was significantly higher in both in vitro and in vivo treated 
retinae when compared to the vehicle controls. Values were quantified by scoring several 
images (open circles) from three retinae (closed circles, n=3) per treatment. Data plotted as 
mean ± SD. One-way ANOVA with Bonferroni multiple comparison test; ***p<0.001; **p<0.01; 
*p<0.05. OS: outer segments; IS: inner segments; ONL: outer nuclear layer; AU: fluorescence 
arbitrary-units. Scale bar: 50µm. 
 
  
.CC-BY-NC-ND 4.0 International licenseperpetuity. It is made available under a
preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in 
The copyright holder for thisthis version posted November 19, 2020. ; https://doi.org/10.1101/2020.11.17.384669doi: bioRxiv preprint 
35 
 
 
Figure 5. VCP inhibition corrects P23H destabilization in rod disk membranes. 
Ultrastructure analysis of longitudinal sections of rod photoreceptor cells using transmission 
electron microscopy (EM) in WT and P23H rat retinae in vitro and in vivo. (A and B) Reynold's 
lead citrate-stained semithin sections of vehicle control and ML240 treated retinae (postnatal 
day 20 and cultivated for 2 days (P20DIV2)) show increased preservation of the outer retina 
and especially of the OS after VCP inhibition. (C) EM of OS from organotypic cultures (PN20 
DIV2) of WT and P23H retinae treated with vehicle or ML240. OS of vehicle-treated P23H 
cultures exhibited numerous vesicotubular structures similar to those described in Haeri and 
Knox, 2012 (55). (D) Schematic model for defective disk formation in OS in the P23H mutant 
(adapted from (55)). In this model and depending on a critical concentration, P23H mutant 
RHO (red dots) begins to self-associate and form aggregates in the membrane, excluding WT 
protein (grey dots). Thus, mutant protein concentrated in a localized area causes defects in 
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the membrane structure, leading to vesiculation followed by disk breakdown. (E) EM of OS 
from WT and P23H untreated retinae in vivo. Only mutant OS display vesicotubular structures. 
(F) EM of OS from P23H of vehicle or ML240- treated retinae in vivo via intravitreal injection. 
Intravitreal injections in P23H rats were performed at postnatal day 10 (PN10) and analysed 
at PN21 (medium-term, as described in Supplementary figure 1). RPE: retinal pigment 
epithelium; OS: rod outer segments; ONL: outer nuclear layer. Scale bar: 1µm. 
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Figure 6. VCP inhibition structurally corrects OS disks in P23H retinae. Graph showing 
the percentage of correctly structured OS of rod photoreceptor cells using transmission 
electron microscopy (EM) in P23H rat retinae in vitro (PN20 DIV2) and in vivo (injected at PN10 
and analyzed at PN21, medium-term, as described in Supplementary figure 1). After treatment, 
in both cultured and in vivo injected groups, the percentage of correctly structured OS in EM 
sections indicated that ML240 treatment significantly preserved the OS structure. Values were 
quantified by scoring several images (open circles) from at least four retinae (closed circles, 
n=3) per treatment. Data plotted as mean ± SD; One-way ANOVA with Bonferroni multiple 
comparison test; ***p<0.001; **p<0.01.  
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Figure 7. Increased light response of in vitro ML240-treated retina. (A) Retinal explants 
(postnatal day 20 and cultivated for 2 days (PN20 DIV2)) treated with ML240 or vehicle were 
excited using light flashes to distinguish the three ganglion cell types ON, OFF, and ON-OFF, 
by the light-triggered spike response patterns. On a multi-electrode array (MEA), retinal activity 
was assessed, recording the inner retinal cell activity (mERG) as well as ganglion cell activity 
(spikes). Light stimulation: 460 nm wavelength, 35 cd/m2 intensity, 3 seconds of light exposure 
time, and 15 seconds flash interval covering a recording area of 340 µm. (B) Light 
responsiveness of the ML240-treated and vehicle-treated retinal explants recording the 
number of spikes and mERG signals. The ordinate presents the percentage of electrodes per 
recording, detecting light-induced activity. (C) Percentage distribution of the activated ganglion 
cell types. (D) Light responsiveness of the retinal explants to repeated 20 light flashes (average 
light response per recording electrode). Data plotted as mean ± SD. Man-Whitney-U test for 
significance: ***p<0.0001. PR: photoreceptor; BC: bipolar cell; HC: horizontal cell; AC: 
amacrine cell; and GC: ganglion cell. 
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Figure 8. Increased light response of the in vivo ML240-treated retina. P23H rats were 
intravitreally injected at PN10, and scotopic ERG responses performed between PN19 and 
PN21 (medium-term). (A) A-wave amplitude at 0 log cd s−1 m−2, (B) Full-field scotopic a-wave; 
(C) b-wave amplitudes were significantly increased in the ML240 treated eyes. As flash 
intensities of light were increased, both a- and b- waves increased proportionately in P23H rats 
injected with ML240. In (A) data plotted as means ± minimum to maximum values, n=11, 
Paired two-sided Student's t-test. In (B) and (C) data plotted as means ± SEM, n=11, Two-way 
ANOVA with Bonferroni multiple comparison test; **p<0.01; *p<0.05. 
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Figure 9. Inhibition of VCP by NMS-873 protects degenerating rod photoreceptors in 
vitro and in vivo in P23H KI mice. (A) Retinae from P23H KI mice were explanted at postnatal 
day 14 (PN14) and kept for 6 days in vitro (DIV6), and treated every second day with either 
NMS-873 or DMSO. Explants were stained with TUNEL assay (green) and antibody against 
RHO (red). NMS-873 treatment restores RHO localization in P23H KI mice retinae explants. 
(B) Bar chart shows the significantly decreased percentage of TUNEL-positive cells in P23H 
KI retinae explants treated with NMS-873 compared to the respective DMSO vehicle control. 
(C) Significant increase in the quantification of the remaining ONL cell rows for the PN20 P23H 
KI fixed retinae treated with NMS-873 compared to the DMSO vehicle control. Single 
intravitreal injection in P23H KI mice was performed at postnatal day 11 (PN11) and analyzed 
at PN21. (D) Representative images of the stained retinae using the TUNEL assay to detect 
cell death (green) and RHO (red) in vivo. (E) Bar chart shows the decreased percentage of 
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TUNEL-positive cells and (F) increased the remaining cell rows in vivo (n=4). The full-field 
scotopic (G) a-wave and (H) b-wave amplitudes were significantly increased in the NMS-873 
treated eyes (n=5). Data plotted as mean ± SEM. (B, C) Unpaired t-test with Welch correction, 
n=4. (E) paired t-test, n=4. (F-H) Two-way ANOVA with Bonferroni multiple comparison test; 
**p<0.01; *p<0.05. RPE: retinal pigment epithelium; ONL: outer nuclear layer; INL, inner 
nuclear layer. Scale bar: 50µm. 
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